Weight-loss drugmakers' stocks get a boost from new Biden proposal on drug coverage, but will it hold up?

Contributing sentiments towards policy:

51% : Novo Nordisk, Eli Lilly and Viking Therapeutics' stocks were all higher premarketThe stocks of companies that make the new class of drugs to treat obesity and manage diabetes were mostly higher early Tuesday after the Biden administration proposed a rule that would allow Medicare or Medicaid to cover the expensive medications.
42% : The costs would greatly increase spending for Medicaid and Medicare and likely squeeze provider payments as states would seek ways to offset them, he said.
40% : Some people may already get coverage of the drugs through Medicare or Medicaid if they have diabetes or are at risk for stroke or heart disease.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.